The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy.
 
Pavlos Msaouel
Honoraria - Exelixis; Pfizer
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Peter F. Thall
No Relationships to Disclose
 
Ying Yuan
Honoraria - Ono Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Midas Medical Technologies; Salzman Group
 
Xuemei Wang
No Relationships to Disclose
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Ipsen; Novartis; Peloton Therapeutics; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Jianjun Gao
Consulting or Advisory Role - ARMO BioSciences; AstraZeneca; crispr therapeutics; Jounce Therapeutics; Nektar; Pfizer; Polaris
Travel, Accommodations, Expenses - AstraZeneca
 
Matthew T. Campbell
Honoraria - Eisai; EMD Serono; Genentech/Roche; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
Research Funding - Exelixis
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Paul Gettys Corn
Research Funding - Exelixis (Inst); Sanofi (Inst)
 
Alda Tam
Honoraria - Endocare; Galil Medical; Merit Medical Systems
Consulting or Advisory Role - Abbvie; Boston Scientific; Jounce Therapeutics; Siemens
Research Funding - AngioDynamics; BTG; Guerbet
Travel, Accommodations, Expenses - Guerbet
 
Kamran Ahrar
No Relationships to Disclose
 
Priya Rao
No Relationships to Disclose
 
Kanishka Sircar
No Relationships to Disclose
 
Hirak Der-Torossian
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Mirati Therapeutics; Nektar; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Nektar; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer; Surface Oncology